Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention relates to a method for treating a skin disorder. In particular, the invention provides a method for treating a skin disorder, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising at least 75% by weight of a main cannabinoid.

The invention relates to a method for treating a skin disorder. In particular, the invention provides a method for treating a skin disorder, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising at least 75% by weight of a main cannabinoid.

The invention relates to a method for treating a skin disorder. In particular, the invention provides a method for treating a skin disorder, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising at least 75% by weight of a main cannabinoid.

In an embodiment, the present disclosure pertains to a lice-treating gel composition. In some embodiments, the composition includes piperonyl butoxide with a concentration from about 0.5 to 5 wt/wt %, pyrethrum with a concentration from about 0.1 to 1 wt/wt %, citronella with a concentration from about 0.1 to 1 wt/wt %, lemongrass oil with a concentration from about 0.01 to 0.5 wt/wt %, and tea tree oil with a concentration from about 0.01 to 0.5 wt/wt %. In an additional embodiment, the present disclosure pertains to a lice-treating gel composition including piperonyl butoxide with a concentration of about 3.889 wt/wt %, pyrethrins with a concentration of about 0.6 wt/wt %, citronella with a concentration of about 0.66 wt/wt %, lemongrass oil with a concentration of about 0.14 wt/wt %, and tea tree oil with a concentration of about 0.1 wt/wt %.

In an embodiment, the present disclosure pertains to a lice-treating gel composition. In some embodiments, the composition includes piperonyl butoxide with a concentration from about 0.5 to 5 wt/wt %, pyrethrum with a concentration from about 0.1 to 1 wt/wt %, citronella with a concentration from about 0.1 to 1 wt/wt %, lemongrass oil with a concentration from about 0.01 to 0.5 wt/wt %, and tea tree oil with a concentration from about 0.01 to 0.5 wt/wt %. In an additional embodiment, the present disclosure pertains to a lice-treating gel composition including piperonyl butoxide with a concentration of about 3.889 wt/wt %, pyrethrins with a concentration of about 0.6 wt/wt %, citronella with a concentration of about 0.66 wt/wt %, lemongrass oil with a concentration of about 0.14 wt/wt %, and tea tree oil with a concentration of about 0.1 wt/wt %.

In an embodiment, the present disclosure pertains to a lice-treating gel composition. In some embodiments, the composition includes piperonyl butoxide with a concentration from about 0.5 to 5 wt/wt %, pyrethrum with a concentration from about 0.1 to 1 wt/wt %, citronella with a concentration from about 0.1 to 1 wt/wt %, lemongrass oil with a concentration from about 0.01 to 0.5 wt/wt %, and tea tree oil with a concentration from about 0.01 to 0.5 wt/wt %. In an additional embodiment, the present disclosure pertains to a lice-treating gel composition including piperonyl butoxide with a concentration of about 3.889 wt/wt %, pyrethrins with a concentration of about 0.6 wt/wt %, citronella with a concentration of about 0.66 wt/wt %, lemongrass oil with a concentration of about 0.14 wt/wt %, and tea tree oil with a concentration of about 0.1 wt/wt %.

Combined multistage microbial preparations for enhancement of the biological skin barrier and maintenance of healthy skin microbiota are disclosed. The preparations are useful in chronic problems associated with dysbiosis such as atopic dermatitis, acne, rosacea and vitiligo or acute problems caused by damage of the skin such as burns, cuts and contusions.

Combined multistage microbial preparations for enhancement of the biological skin barrier and maintenance of healthy skin microbiota are disclosed. The preparations are useful in chronic problems associated with dysbiosis such as atopic dermatitis, acne, rosacea and vitiligo or acute problems caused by damage of the skin such as burns, cuts and contusions.